SNY - Rallybio in-licenses preclinical antibody candidate from Sanofi

The clinical-stage biotech Rallybio Corporation (NASDAQ:RLYB) said on Tuesday it received the worldwide exclusive rights to KY1066, a monoclonal antibody developed by Sanofi (SNY) to treat blood disorders such as beta-thalassemia (BT) and a group of myelodysplastic syndromes (MDS). With the transaction, Rallybio (RLYB) has renamed the pre-clinical asset RLYB331 as it transforms it into clinical development following further studies. The candidate, designed to address a significant unmet need in patients with severe anemia with ineffective erythropoiesis and iron overload, expands the company’s pipeline focused on hematology, Rallybio (RLYB) said. Per the terms, the company is expected to make a $3M upfront cash payment to Sanofi (SNY) in addition to milestones payments and mid to high single-digit royalties on net sales. “With our strong focus on portfolio expansion, the in-licensing of RLYB331, our first as a public company, marks a pivotal moment for Rallybio,” Chief Executive Martin Mackay remarked.

For further details see:

Rallybio in-licenses preclinical antibody candidate from Sanofi